News Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
2.35 ^USD	+2.84%		-18.97%	-42.54%

29/02	Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024
29/02	Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024	16/04	AQ
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case	03/04	AQ
Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024	01/03
Organogenesis: Q4 Earnings Snapshot	01/03	AQ
Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q4 Revenue $99.7M, vs. Street Est of $109.1M	01/03	MT
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance	01/03	AQ
Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024	01/03	CI
Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference	12/02	AQ
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024	09/02	AQ
Organogenesis Holdings Insider Sold Shares Worth $940,860, According to a Recent SEC Filing	12/01	MT
BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating	27/12	MT
HippoFi Hires World's Top Regenerative Therapy Expert, Dr. Gail Naughton, to Drive Commercialization Plans of its Proprietary Technologies	12/12	AQ
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	07/12	BU
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating	14/11	MT
Organogenesis: Q3 Earnings Snapshot	10/11	AQ
Transcript : Organogenesis Holdings Inc., Q3 2023 Earnings Call, Nov 09, 2023	10/11
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q3 Revenue $108.5M, vs. Street Est of $111.4M	10/11	MT
Organogenesis Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Summary

Filters